ArticleFrontiers in oncology2022

Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults.

Jessica Bodea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.